GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Cyclically Adjusted PS Ratio

Xbrane Biopharma AB (OSTO:XBRANE) Cyclically Adjusted PS Ratio : 0.36 (As of Jun. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Cyclically Adjusted PS Ratio?

As of today (2024-06-06), Xbrane Biopharma AB's current share price is kr0.323. Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr0.90. Xbrane Biopharma AB's Cyclically Adjusted PS Ratio for today is 0.36.

The historical rank and industry rank for Xbrane Biopharma AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

OSTO:XBRANE' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.22   Med: 0.27   Max: 0.41
Current: 0.33

During the past years, Xbrane Biopharma AB's highest Cyclically Adjusted PS Ratio was 0.41. The lowest was 0.22. And the median was 0.27.

OSTO:XBRANE's Cyclically Adjusted PS Ratio is ranked better than
93.65% of 504 companies
in the Biotechnology industry
Industry Median: 5.525 vs OSTO:XBRANE: 0.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xbrane Biopharma AB's adjusted revenue per share data for the three months ended in Mar. 2024 was kr0.043. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr0.90 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Xbrane Biopharma AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Xbrane Biopharma AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Cyclically Adjusted PS Ratio Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.33

Competitive Comparison of Xbrane Biopharma AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Xbrane Biopharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Cyclically Adjusted PS Ratio falls into.



Xbrane Biopharma AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Xbrane Biopharma AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.323/0.9
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Xbrane Biopharma AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.043/132.2054*132.2054
=0.043

Current CPI (Mar. 2024) = 132.2054.

Xbrane Biopharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 100.541 0.000
201409 0.000 100.161 0.000
201412 -0.061 100.225 -0.080
201503 0.050 99.950 0.066
201506 0.036 99.995 0.048
201509 0.006 100.228 0.008
201512 0.006 100.276 0.008
201603 0.025 100.751 0.033
201606 0.024 101.019 0.031
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 0.155 102.022 0.201
201706 0.095 102.752 0.122
201709 0.000 103.279 0.000
201712 0.186 103.793 0.237
201803 0.161 103.962 0.205
201806 0.082 104.875 0.103
201809 0.038 105.679 0.048
201812 1.653 105.912 2.063
201903 0.000 105.886 0.000
201906 0.000 106.742 0.000
201909 0.000 107.214 0.000
201912 0.004 107.766 0.005
202003 0.000 106.563 0.000
202006 0.000 107.498 0.000
202009 0.000 107.635 0.000
202012 0.038 108.296 0.046
202103 0.013 108.360 0.016
202106 0.013 108.928 0.016
202109 0.010 110.338 0.012
202112 0.014 112.486 0.016
202203 0.033 114.825 0.038
202206 0.085 118.384 0.095
202209 0.064 122.296 0.069
202212 0.073 126.365 0.076
202303 2.247 127.042 2.338
202306 0.205 129.407 0.209
202309 0.228 130.224 0.231
202312 0.255 131.912 0.256
202403 0.043 132.205 0.043

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xbrane Biopharma AB  (OSTO:XBRANE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Xbrane Biopharma AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (OSTO:XBRANE) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (OSTO:XBRANE) Headlines

No Headlines